Scalable and Cost-Effective DNA Methylation Profiling to Accelerate Precision Medicine
| Reference number | |
| Coordinator | NEXUS Epigenomics AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | November 2025 - July 2026 |
| Status | Ongoing |
| Venture | Innovative Startups |
| Call | Innovative Startups 2025 |
Purpose and goal
The goal is to validate MeTLAND®, a cost-effective DNA methylation profiling technology, for use in precision medicine. The project aims to develop robust SOPs for clinical samples, create a tailored data-analysis pipeline, and engage pilot users to demonstrate MeTLAND’s value in translational and biopharma settings.
Expected effects and result
The project will deliver validated workflows, a methylation data-analysis pipeline, and pilot collaborations with translational researchers and pharma. These results will demonstrate MeTLAND’s potential to accelerate biomarker discovery, enable scalable precision medicine, and strengthen Sweden’s position in epigenomic innovation.
Planned approach and implementation
We will first develop SOPs and QC standards for diverse clinical sample types, then design and validate a methylation data-analysis pipeline. Finally, we will onboard pilot users to test the complete workflow. Progress will be evaluated through defined milestones, user feedback, and data quality metrics.